^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Solid Tumor
    Drug:elimusertib (BAY 1895344) (ATR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

    Published date:
    09/28/2020
    Excerpt:
    ...The ORR in patients with ATM aberrations (ATM protein expression loss and/or ATM deleterious mutation) across all dose levels was 36.4% (4/11 patients)….BAY 1895344 is tolerable and has antitumor activity in heavily pre-treated patients with a range of advanced solid tumors, particularly those with ATM deleterious mutations...
    DOI:
    10.1158/2159-8290.CD-20-0868